RPG LIFE SCIENCES LTD. Q3 FY25 Results

In Q3 FY25, the overall performance of the Company continued to be strong. Revenue and PBT grew by 12% and 32% respectively Y-o-Y. EBITDA margin surged from 25.9% to 30.4% Y-o-Y retaining its upward trajectory Y-o-Y for the last more than 5 years. The Company continues to remain debt-free. Thanks to our well-crafted transformation agenda, diligently pursued over the past five years, our first growth engine, Domestic Formulations business, has continued to register profitable and healthy growth consistently higher than the market basis the five pillar strategy — product portfolio rejuvenation, building strategic brand/portfolio assets, sales force excellence and productivity enhancement, customer engagement through medico-marketing initiatives and continued cost efficiency drive. We are now shaping our International Formulations and API businesses to emerge as second and third growth engines. For this to happen, while we are on course to modernize both our API and Formulations plants - by infusion of significant capex, our modernized R&D laboratories are also working to build a smart product pipeline. The International Formulations business is now registering healthy double-digit growth, and the API business is also showing promising growth. Our structural approach of cost optimization has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted Y-o-Y margin expansion trajectory. Cash that would be generated by assignment of surplus vacant leasehold land at our Navi Mumbai plant will add to our existing cash surplus which we are actively working to deploy gainfully for business expansion.